SecBot SecBot
144 ·Filed Nov 9, 2026

RCKT

ROCKET PHARMACEUTICALS, INC.
NEUTRAL
Impact 2/10
Horizonimmediate Processed7d 11h ago SEC0001959173-26-007868
Form 144: notice of proposed sale of securities
Actionable Insight • Neutral

This is a routine tax-withholding sale tied to equity vesting, not a discretionary insider sale. No signal of changing insider sentiment. Monitor future Form 4 filings for any discretionary sales by officers.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5
Entry
$2.53
T+0 close · Nov 9, 2026 · via day close
Latest settled
−14.62%
T+5 · $2.16
Vs SPY
−12.93%
α at T+5
Next horizon
T+20
in 21d
  1. T+0 · Nov 9 $2.53entry
  2. T+1 · 7d ago −3.16%α −2.79% · $2.45
  3. T+5 · 20h ago −14.62%α −12.93% · $2.16
  4. T+20 · in 21d Pending
  5. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Christopher James Stevens, an officer of Rocket Pharmaceuticals, filed a Form 144 notice to sell 16,131 shares of common stock valued at approximately $37,530. The shares were acquired via restricted stock vesting on November 4, 2026, and the sale is intended to cover a tax obligation from the settlement of a vested equity award. This is a routine insider sale for tax withholding purposes, not a discretionary portfolio liquidation.

Key Facts

  • Reporting person: Christopher James Stevens, an officer of Rocket Pharmaceuticals
  • Shares to be sold: 16,131 shares of common stock
  • Estimated value: $37,530.38
  • Shares acquired on November 4, 2026 via restricted stock vesting from the issuer
  • Sale purpose: cover tax obligation from vested equity award distribution
  • Broker: Fidelity Brokerage Services LLC
  • Filing date: November 9, 2026
  • Market cap of issuer: $267M

Financial Impact

Sale of 16,131 shares valued at ~$37,530, representing about 0.014% of market cap

dilution

Risk Factors

  • Form 144 is an intent to sell; the actual sale may not occur
  • No other insider trading context provided to assess pattern

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
60% bullish (20 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001959173-26-007868
Document: 0001959173-26-007868-index.html0001959173-26-007868
Document: 0001959173-26-007868.txt0001959173-26-007868

Track record

21 reports on RCKT

Performance horizon

5 of 6 bullish or bearish reports moved the stock their way by T+20. Best: +42.18% at T+20 after the Jun 12, 2026 report. 6 of 6 went positive at some point.

Filters
  1. Nov 13, 20263d ago 144 Neutral 2/10 Entry $2.45 Now $2.16 −11.84% settles Dec 15
  2. Nov 13, 20263d ago 144 Neutral 2/10 Entry $2.30 Now $2.16 −6.09% settles Dec 14
  3. Nov 12, 20264d ago Insider Cluster Neutral 3/10 Entry $2.30 Now $2.16 −6.09% settles Dec 14
  4. Nov 12, 20264d ago 8-K Neutral 5/10 Entry $2.30 Now $2.16 −6.09% settles Dec 14
  5. Nov 9, 20267d ago 144 Neutral 2/10 Viewing Entry $2.53 Now $2.16 −14.62% settles Dec 8
  6. Nov 9, 20267d ago 144 Neutral 2/10 Entry $2.53 Now $2.16 −14.62% settles Dec 8
  7. Nov 5, 202611d ago 144 Neutral 2/10 Entry $2.44 Now $2.16 −11.29% settles Dec 4
  8. Oct 30, 202617d ago SC 13G/A Neutral 2/10 Entry $2.44 Now $2.16 −11.48% settles Nov 30
  9. Oct 6, 20265w ago 8-K Bullish 7/10 Entry $2.54 to $2.57 Now $2.16 −14.79% ▲ +1.38% +2.62% vs SPY
  10. Sep 15, 20268w ago 8-K Bullish 7/10 Entry $3.41 to $2.30 Now $2.16 −36.66% ▼ −32.55% −35.27% vs SPY
Showing 10 of 21

US Market Status

Market Closed · Opens in 6h 41m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 9, 2026